Clinical Trial for Type 2 Diabetes
Clinical Trial for Type 2 Diabetes.
The role of GLP-1 in blood glucose, triglyceride and energy expenditure responses to fat in type 2 diabetes.
When we ingest a meal a number of hormones, including glucagon-like peptide-1 (GLP-1), are released from the small intestine. These hormones play an important role in regulating the motor function of the gut, blood pressure, the levels of sugar and fat in the blood, and the rate at which the body uses energy. The effect of these hormones is, however, limited by the fact that they undergo rapid degradation by an enzyme in the blood. There is a new class of type 2 diabetic drugs that act by inhibiting this enzyme, and as a result, these drugs improve blood glucose levels. We have recently shown that these drugs (e.g. vildagliptin) also enhance metabolic rate (an effect that may prevent weight gain) and decrease levels of triglycerides in the blood in healthy volunteers. This study aims to determine if these drugs have the same effects during fat infusion in patients with type 2 diabetes, and to determine the specific role of the gut hormone, glucagon-like peptide-1 (GLP-1) in mediating these responses.
Unable to participate in this trial? Register for similar trials.